In study ARG-911, 304 patients having clinically diagnosed HIT (n = 160) or HITTS (n = 144) received argatroban at a mean dose of 2.0 mg/kg/min for an average of 6 days. This study also enrolled 193 historical controls (HIT, n = 147; HITTS, n = 46). Although not required for enrollment, laboratory confirmation of HIT antibodies occurred in 57% of the argatroban-treated patients and 77% of controls; the remaining individuals were either never tested or had a negative result (Lewis et al., 2001).

0 0

Post a comment